Introduction {#Sec1}
============

Mega-prosthetic replacement of the proximal femur has become a standard procedure to treat primary bone tumors, metastases and large bone defects after orthopedic surgeries using a large, special type of total hip arthroplasty (Fig. [1](#Fig1){ref-type="fig"}). The orthopedic surgeon must understand the reasons for postoperative complications to avoid them and ensure that the patient has a high-quality postoperative outcome. Although various complications occur after the implantation of these prostheses, aseptic loosening rates are of particular interest because they are notably higher than after standard total hip arthroplasty (5--27 %) \[[@CR1]--[@CR3]\]. A large meta-analysis recently demonstrated that nicotine consumption was associated with higher aseptic loosening rates after standard total hip arthroplasty \[[@CR4]\]. However, smoking has not been established as a risk factor for aseptic loosening after mega-prosthetic proximal femoral replacement. Considering the aforementioned recent study results regarding standard total hip arthroplasty, we hypothesized that smoking habits also influence the aseptic loosening rates of mega-prosthetic proximal femoral replacement. Therefore, this study sought to test the correlation between the aseptic loosening of these prostheses and nicotine consumption.Fig. 1Proximal femur replacement

Materials and methods {#Sec2}
=====================

Protocol {#Sec3}
--------

In accordance with our unpublished study protocol 'Nicotine consumption and proximal femoral replacement: a 10-year single-center analysis', the present study was designed as a retrospective, single-center study with a one-time cross-sectional functional follow-up assessment for all surviving patients. We planned to include at least 20 patients with seven different surgeons in this study. To support our hypothesis, the patients would be segregated into smoking and non-smoking groups, and the aseptic loosening rates would be compared between groups. Smokers were defined as patients who had consumed nicotine before and after implantation of the femoral mega-prosthesis, whereas all other patients were defined as non-smokers. Aseptic loosening was defined based on pain upon ambulation and radiological evidence of periprosthetic bone resorption without signs of infection (via culture-positive swabs or blood samples). Radiological evidence of periprosthetic bone resorption was obtained using standardized X-rays (antero-posterior and Lauenstein's oblique lateral projection) that were independently evaluated by a radiologist and an orthopedic surgeon. A microbiologist analyzed intraoperatively obtained swabs that were considered positive when the same bacteria were present in two of five swabs or when the patient had additional signs of bacteremia (elevated C-reactive protein \[CRP\] levels or leukocytosis).

Statistical analyses {#Sec4}
--------------------

The differences in aseptic loosening rates between the groups of smokers and non-smokers were analyzed using Fisher's two-tailed exact test because it is reliable for small sample sizes. In addition, a Kaplan--Meier analysis was used to evaluate the patient and prosthesis survival rates. The means, standard deviations (SDs), medians and ranges were calculated for all data. All statistics were computed using StatSoft, Inc. (2014) STATISTICA data analysis software (StatSoft, Inc., Tulsa, OK, USA), version 12.0.

Methodological approach {#Sec5}
-----------------------

To obtain our study group, we requested information from the controlling department of our hospital, where all diagnoses and procedures are matched to the treated patients and retained. All potential cases of proximal mega-prosthetic femoral replacement between 2005 and 2015 were identified according to the International Classification of Procedures in Medicine (ICPM) figures that were used to code operations involving femoral replacement with special prostheses (confer Supplementary Material). All patient files and X-rays were reviewed, and all patients who received special femur prostheses other than a proximal femoral replacement were excluded. Only cases in which the surgical procedure was comparable with that used for these implants were included (i.e., transection of the proximal femur in the subtrochanteric region and replacement of the proximal part using an implant with a large monopolar femoral head and a cone for intramedullary insertion into the femur). Only those cases in which the implants were cemented and not attached to the bone with additional screws or plates were included.

Patient baseline characteristics {#Sec6}
--------------------------------

Baseline data including sex, age and preoperative data regarding body mass index (BMI), American Society of Anesthesiologists (ASA) physical status \[[@CR5]\], number and type of concomitant diseases, number and type of medications, alcohol consumption and use of illicit drugs were documented based on the available patient files. The surgical protocols were reviewed, and the data regarding the implant manufacturer, operating surgeon, cementation, implants at the surgical site prior to implantation, intraoperative complications and duration of surgery were recorded. The postoperative period was investigated, and data were recorded regarding the application, type and amount of postoperative antibiotics, duration of bed rest, duration of days until fully weight bearing, rehabilitation after inpatient treatment, postoperative chemotherapy or radiation, duration of inpatient treatment and postoperative complications.

Nicotine consumption and aseptic loosening {#Sec7}
------------------------------------------

Next, the data regarding nicotine consumption prior to surgery were recorded. Smoking habits (i.e., amount and duration in cigarette pack years \[py\], consumption of tobacco via cigar, pipe or snuff tobacco) prior to surgery were documented based on patient files because the ward nurses routinely record this information for every patient upon admission. To determine postoperative nicotine consumption, the patients (or their living relatives when the patients were deceased) were contacted and interviewed about their smoking habits after proximal femur replacement.

All of the documentation from the patient follow-up assessments and subsequent operations with the attendant X-rays were then reviewed to determine how many patients from each group developed aseptic loosening.

Functional follow-up assessment {#Sec8}
-------------------------------

All living patients were invited to complete a functional follow-up assessment at our clinic. These evaluations were performed using the harris hip score (HHS) \[[@CR6]\], toronto extremity salvage score (TESS) \[[@CR7]\], musculoskeletal tumor society score (MSTS) \[[@CR8]\] and short form 36 (SF36) \[[@CR9]\]. Moreover, leg length was recorded for every patient and compared with the documentation in their files or measured at the functional follow-up assessment.

Results {#Sec9}
=======

Methodological approach {#Sec10}
-----------------------

A total of 225 cases of special femoral prostheses implantation were identified. All of the patient files and X-rays were reviewed, resulting in the exclusion of 198 patients who had not received a proximal femoral replacement but a different femoral prosthesis or had undergone a surgical procedure that differed from the study protocol.

Patient baseline characteristics {#Sec11}
--------------------------------

Twenty-six patients who received proximal femoral replacements were included in this study. Fourteen women and 12 men received 27 prostheses, including one patient who received bilateral prostheses. All protheses stems were cemented with gentamicin-loaded polymethylmethacrylate bone cement. The indications were metastatic bone disease in 16 cases, malignant primary bone tumors in six cases, bone loss after orthopedic surgery in four cases and a benign bone tumor in one case (Table [1](#Tab1){ref-type="table"}).Table 1Patient baseline characteristics and complicationsPatientGenderAgeDMRANicotineReason for replacementImplant at hip prior to operationManufacturer1M76.0----NSMetastasis urothel-carcinoma--Cremascoli2M66.8----S (49 py)Malignant histiocytoma--Cremascoli3F66.9----NSMetastasis mamma-carcinoma--Implantcast4F75.4----NSMetastasis mamma-carcinoma--LINK5F62.3Yes--NSMetastasis mamma-carcinoma--Implantcast6M73.6----NSPlasmocytomaStandard hip endoprosthesisImplantcast7F66.9Yes--NSPlasmocytoma--Implantcast8M73.3----S (52 py)Metastatic adenocarcinoma prostate--Implantcast9M37.6----S (20 py)Chondrosarcoma--Implantcast10 left legF60.0----NSMetastasis mamma-carcinomaIntramedullary femur nailImplantcast10 right legF59.8----NSMetastasis mamma-carcinomaIntramedullary femur nailImplantcast11M55.4----S (36 py)Fibrous dysplasia, pathological fracture--Implantcast12F56.6----NSMetastasis mamma-carcinomaIntramedullary femur nailEska Implants13M56.2----NSMetastatic renal cell carcinoma--Eska implants14F77.5YesYesNSBone loss after osteosynthesisIntramedullary femur nailEska implants15F66.4----NSMetastatic renal cell carcinomaMetal plateEska implants16M52.9----NSMetastatic renal cell carcinoma--Eska implants17F75.7----NSMetastatic renal cell carcinoma--Eska implants18M81.7----S (67 py)Bone loss after removal of hip prosthesisStandard hip endoprosthesisEska Implants19M59.7----NSChondrosarcomaStandard hip endoprosthesisImplantcast20F74.0----NSPlasmocytomaIntramedullary femur nailEska implants21F66.6----NSMetastasis mamma-carcinomaIntramedullary femur nailEska implants22F72.8----NSBone loss after removal of hip prosthesisStandard hip and knee endoprosthesisEska implants23M70.4----NSMetastatic renal cell carcinoma--Orthodynamics24F57.6----NSBone loss after osteosynthesisIntramedullary femur nailOrthodynamics25M77.1YesYesNSMetastasis bronchial adenocarcinoma--Orthodynamics26F60.9----NSMetastasis mamma-carcinoma--OrthodynamicsPatientDuration of\
operation\
(min)Intra-/postoperative complicationsTime primary operation-first following operationReasons for all implant related following operationsAmount of following related operationsTime to removal of implant\
(months)Situation after implant removalTime from implantation yo death or alive1267--/Wound infection, lymphatic edema10.2 monthsSuperficial infection (enterococcus faecalis, staphylococcus epidermidis)10.9 years2--/Hematoma, dislocation \<3 months after surgery1 dayHematoma, dislocation21.0 years3158--/--0.4 years4146--/--0.6 years5143--/--3.0 years6260--/Dislocation \>3 months after surgery1.3 years7108--/--1.7 years8155--/--0.1 years9300--/Aseptic shaft loosening71.0 monthsAseptic shaft loosening171.0Re-implantated proximal cemented femoral replacementAlive10 left leg--/Dislocation \>3 months after surgery3.3 years10 right leg--/--3.5 years11229--/Aseptic shaft loosening12.0 monthsAseptic shaft loosening112.0Re-implantated proximal cemented femoral replacementAlive12273--/Wound infection, urinary tract infection6.0 monthsSuperficial infection (staphylococcus epidermidis, corynebacterium species)40.8 years13242--/Wound infection5.2 monthsSuperficial infection (staphylococcus aureus)10.5 years14306--/Sigma diverticulitis0.7 years15201--/Wound healing deficiency without infection4.2 monthsWound healing deficiency without infection10.9 years16269--/Dislocation \<3 months after surgery2.4 monthsDislocation15.3 years17219--/--Alive18341Femoral vein lesion / aseptic shaft loosening45.5 monthsAseptic shaft loosening145.5Total femoral replacementAlive19--/Gluteal insufficiency, local tumor recurrence82.9 monthsLocal tumor recurrence182.9Hip ex-articulation without implantAlive20240--/Dislocation \>3 months after surgery, recurrent43.3 monthsDislocation1Alive21244--/Wound infection, hematoma, urinary tract infection0.4 monthsSuperficial infection (staphylococcus haemolyticus), hematoma20.7 years22295--/Wound infection12.5 monthsDeep infection/septic loosening (MRSA, MRSE, staphylococcus capitis, campylobacter fetus)513.9Girdlestone situation with attendant femoral amputationAlive23240--/Dislocation \>3 months after surgeryAlive24220--/--Alive25183--/Dislocation \>3 months after surgery0.4 years26224--/--Alive*M* male, *F* female, *NS* non-smoker, *S* smoker, *DM* diabetes mellitus, *RA* rheumatoid arthritis, *Py* pack years of nicotine consumption, *MRSA* methicillin-resistant *staphylococcus aureus*, *MRSE* methicillin-resistant *staphylococcus epidermidis*

The average age at surgery was 65.9 years (SD ± 9.9, median 66.8, range 37.6--81.7) with an average BMI of 27.4 (SD ± 5.6, median 26.0, range 16.4--41.1). The patients had 4.4 concomitant diseases on average (SD ± 2.1, median 5.0, range 1.0--7.0) and were prescribed 5.4 medications on average (SD ± 3.5, median 5.0, range 1.0--14.0). The average ASA score at surgery was 2.5 (SD ± 0.6, median 3.0, range 1.0--3.0).

The average duration of surgery was 228.8 min (SD ± 59.2, median 240.0, range 108.0--341.0). Only one of 27 surgeries produced an intraoperative complication (femoral vein lesion). This lesion was sutured immediately and healed without further incident. During the postoperative period, the average duration of bed rest was 6.3 days (SD ± 4.4, median 7.0, range 0.0--14.0), and the average number of days until patients were fully weight bearing was 27.4 (SD ± 23.8, median 16.5, range 0.0--100.0). Twenty-three of 27 patients received postoperative antibiotics (18 received cefuroxime; five received cefuroxime and clindamycin) for an average of 26 days (SD ± 33.7, median 10.0, range 3.0--90.0). Inpatient treatment lasted 31.0 days on average (SD ± 16.5, median 27.0, range 8.0--94.0). Sixteen of 27 patients underwent postoperative rehabilitation. The application of postoperative chemotherapy was documented for 7 of 27 patients, and postoperative radiation was documented for 9 of 27 patients. Three of our patients regularly consumed alcohol, but none of these patients used illicit drugs.

Nicotine consumption and aseptic loosening {#Sec12}
------------------------------------------

Five patients were smokers, whereas 21 patients were non-smokers. The smokers consumed nicotine via cigarettes prior to implantation for an average of 44.8 py (SD ± 17.7, median 49, range 20--67). None of the patients ingested tobacco via cigar, pipe or snuffing. After an average follow-up period of 2.7 years (SD ± 2.3, median 1.7, range 0.1--7.9), the X-rays revealed signs of bone resorption in four of 27 prostheses (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Aseptic loosening

One of these patients showed microbiological testing results indicating infection with methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-resistant *S. epidermidis* (MRSE) with leukocytosis and elevated CRP levels. Thus, this patient was classified as having septic loosening. This patient underwent a girdlestone procedure with additional above-knee amputation due to concomitant infection of the adjacent knee prosthesis.

The remaining three patients did not show bacterial growth according to microbiological tests and did not have signs of infection in their blood; hence, they were classified as having aseptic loosening. Throughout the course of the follow-up assessments of two of these patients, the proximal femoral replacement was exchanged for a similar proximal mega-prosthesis, whereas the third patient received a total femoral replacement. All three of these patients were smokers, whereas none of the non-smokers developed aseptic loosening. Fisher's two-tailed exact test revealed a significant relationship between nicotine consumption (smoking) and aseptic loosening (*p* = 0.003).

Functional follow-up assessment {#Sec13}
-------------------------------

Ten of 26 patients were alive at the time of this study, with eight of 27 prostheses remaining; all of these patients were available for a functional follow-up assessment (Table [2](#Tab2){ref-type="table"}). No patient death (16/26) was related to the implantation of the mega-prosthesis or to any subsequent complication. The average age at the follow-up assessment was 69.2 years (SD ± 12.5; median 70.9; range 44.6--86.7). The time from primary implantation to the follow-up assessment was 4.7 years on average (SD ± 2.2; median 4.8; range 0.8--7.9). Of the 10 survivors, five had the original implant; however, the implant was removed from the hips of the other five patients. The average time between implantation and removal was 45.1 months (SD ± 32.3; median 45.5; range 12.0--82.9). Apart from the aforementioned three cases of aseptic loosening and one case of septic loosening, one patient underwent hip ex-articulation because of local tumor recurrence (chondrosarcoma). Another patient was wheelchair-bound due to Parkinson's disease and multiple osteoporotic spinal fractures. A Kaplan--Meier analysis revealed that the prosthesis survival rates were generally higher than the patient survival rates (Fig. [3](#Fig3){ref-type="fig"}).Table 2Functional follow-upPatientAge at follow-up (years)Time from implantation until functional follow-up (years)Hip situation at follow-upKnee society score (%)Harris hip score (%)Toronto extremity salvage score (%)Musculoskeletal tumor society score (%)Musculoskeletal tumor society score (points out of 30)Short form 36 physical functioning944.67.1Proximal cemented femoral replacement73.65015301161.86.4Proximal cemented femoral replacement---wheelchair bound due to Parkinson's disease and osteoporotic spinal fractures34103201780.75.0Proximal cemented femoral replacement908593.3281001886.75.0Total femoral replacement8365575015251967.67.9Hip ex-articulation764012352078.64.6Proximal cemented femoral replacement5152.833.310152276.84.0Girdlestone situation with femur amputation48.363.319102374.23.8Proximal cemented femoral replacement7264.356.717252459.62.0Proximal cemented femoral replacement9491.196.729752661.70.8Proximal cemented femoral replacement9368802450PatientShort form 36 role-physicalShort form 36 bodily painShort form 36 general healthShort form 36 vitalityShort form 36 social functioningShort form 36 role-emotionalShort form 36 mental healthShort form 36 physical component summary measureShort form 36 mental component summary measure91008420302533.34442.929.711010203012.502425.126.117100100679510010010053.761.81810084525587.51006839.255.519062777587.51007230.662.220041205010005224.945.72204167507505229.942.823506457551001009628.567.2247510025551001004447.646260100402010004042.932.9 Fig. 3Kaplan−Meier analysis

The six patients with proximal femoral replacements who had the ability to walk had an average TESS of 72.5 % (SD ± 14.0; median 70.8; range 52.8--91.1), an average MSTS of 68.3 % (SD ± 25.5; median 68.4; range 33.3--96.7), and an average SF36 physical component summary score of 40.1 points (SD ± 11.2; median 42.9; range 24.9--53.7), whereas the average SF36 mental component summary score was 47.2 points (SD ± 15.0; median 45.9; range 29.7--67.2). The HHS of all patients with a functioning hip mega-prosthesis was 77.5 % on average (SD ± 17.7; median 81.0; range 51.0--94.0). The leg length measurement based on patient files or the functional follow-up assessment showed an average difference of −0.3 (±0.9 SD) cm (median 0.0; range −1.5 to 1.0) between the prosthesis leg and the healthy contralateral side.

Discussion {#Sec14}
==========

Aseptic loosening and nicotine consumption {#Sec15}
------------------------------------------

The principal result of this study revealed that smoking is related to aseptic loosening in the mega-prosthetic replacement of the proximal femur. Thus, our hypothesis was valid for the present sample.

The aseptic loosening rate observed in this study (3/27) was comparable with the rates published in literature ranging from 5−27 % \[[@CR1]--[@CR3]\]. No other studies have identified smoking as a risk factor for aseptic loosening after the mega-prosthetic replacement of the proximal femur. However, the effects of smoking regarding the rates of aseptic loosening for other hip implants and bone healing are controversial. Some studies have not found a correlation between smoking and aseptic loosening after total hip arthroplasty \[[@CR10], [@CR11]\], whereas other studies have shown a correlation between smoking and aseptic loosening after total hip arthroplasty \[[@CR12]\] as well as between smoking and revision total hip arthroplasty \[[@CR13]\]. The latter observation is supported by our data.

Biochemically, several clues indicate how nicotine slows bone healing. Nicotine, through the activation of the cholinergic anti-inflammatory pathway, might partially and indirectly slow bone healing by inhibiting tumor necrosis factor-α (TNF-α) secretion \[[@CR14]\]. TNF-α appears to be part of a cascade that leads to the expression of crucial proteolytic enzymes (matrix metalloproteinases 9, 13 and 14), which are necessary in fracture healing to progress from the soft callus stage to endochondral ossification \[[@CR4], [@CR15], [@CR16]\]. Thus, the bone remains soft for a prolonged period in their absence. Delayed bone healing after the implantation of a proximal mega-prosthetic femoral replacement is extremely problematic because the femur and the implanted prosthesis must bear the patient's full bodyweight during normal ambulation and stair climbing. During normal ambulation, this force can be 2.3 times the patient's bodyweight \[[@CR17]\]. Presumably, this delayed bone healing causes the unwanted prolonged motion of the implant within the bone and hinders proper osseointegration, thereby leading to aseptic loosening, even when the prosthesis is cemented.

In conclusion, smokers require special counseling before and after implantation of a mega-prosthetic replacement of the proximal femur to cease or at least reduce their smoking habits. They must be informed about their increased risk for aseptic loosening.

Functional follow-up assessment: patient and prosthesis survival {#Sec16}
----------------------------------------------------------------

The recent follow-up assessment revealed satisfactory results for all of the patients who survived with a functional hip prosthesis. This finding corroborates the current literature, which shows that successful functional results can be achieved for most patients after implantation of a mega-prosthetic replacement of the proximal femur \[[@CR18], [@CR19]\]. The Kaplan--Meier analysis showed that the cumulative survival of the prostheses was generally longer than the cumulative survival of the patients. In fact, the low patient survival rates were because of metastatic tumor diseases, which are the most common reasons for the implantation of these prostheses. After 7 years, we observed that prosthesis survival fell below patient survival. However, censoring of patients explains this change. Time will reveal how long the survivors will live with their prostheses and whether this effect will remain after additional years of observation.

Limitations {#Sec17}
-----------

One limitation of this study was clearly its small sample size. Because we included all of our patients with these types of prostheses over the past 10 years in this study, we were unable to increase our sample size. Although seven orthopedic surgeons performed this operation over the past decade, the surgical procedure, according to the study design, was the same for all of the patients and therefore provided comparable results. Apart from smoking, we were unable to identify any other factor that influenced aseptic loosening. Therefore, matching the smokers with comparable non-smokers based on sex, age, BMI, indication for operation, duration of operation, chemotherapy, radiation and implant at the surgical site prior to implantation would not have changed the results. However, we concede that matching was not possible because of the lack of appropriate matching partners. In addition, heterogeneous indications for implantation (malignant vs benign) and comorbidities led to strong differences regarding the survival rates of the patients.
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